Skip to main content
OpenTrials
Completed

NCT Number: NCT05252832

Superficial Cervical Plexus Block for IJCL Pain Management

This is a prospective randomized trial evaluating the effect of SCPB on reported patient pain following IJCL placement as compared to local infiltrate.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cleveland Clinic Akron General

Akron, Ohio, 44307, United States

About this study

The goal of this study is to determine if SCPBs provide more pain control than local infiltrate of anesthetic for internal jugular venous cannulation. The investigators hypothesis that patients who receive the SCPB will have a lower VAS rating on average than those who receive local infiltration following internal jugular venous cannulation. To test this, the investigators will be approaching eligible patients for inclusion in a research study. If the patients consent, the patients will be randomly assigned the standard of care treatment or the SCPB. The investigators will then ask the patients to rate pain following insertion of the central line. The investigators will also evaluate different aspects of the patient's hospital course to evaluate their outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are 18 years and older, and;
  • Present to the Akron General Emergency Department (Main) between March 1, 2021 and December 1, 2022, and;
  • Require IJVC as a part of their clinical care.

Exclusion criteria

  • Patients who are intubated; or
  • Patients who undergo CPR; or
  • Patients who have an allergy to lidocaine or bupivacaine; or
  • Patients who have a contraindication to receiving a superficial cervical plexus block such as cellulitis over Erb's point or the internal jugular vein, abnormal anatomy, or prior surgery to the area.

Treatment and study plan

Superficial Cervical Plexus Block

Procedure

Location of injection for block.

Local Infiltrate

Procedure

Local infiltration location.

Primary outcomes

  1. Visual Analog Scale Rating

    Time frame: 30 minutes post central line placement

    The average Visual Analog Scale (VAS) rating in patients who receive the SCPB during internal jugular venous cannulation versus the average VAS in patients receiving local infiltration. The scale is from 0-10, with 0 meaning no pain and 10 meaning the most pain I have ever experienced.

Secondary outcomes

  1. Complications

    Time frame: Duration of emergency department and inpatient encounter, typically no more than 7 days.

    To determine if SCPBs are associated with higher complication rates than local infiltration with internal jugular venous cannulation. Complications will be defined as arterial injury, lacerations of the vena cava, mediastinal vessels, and right atrium, hematoma formation, retained guide wire, pulmonary complications including pneumothorax, pneumomediastinum, chylothorax, tracheal injury, injury to the recurrent laryngeal nerve, and air embolus, tracheal injury, arrhythmia, cardiac arrest, device dysfunction, device infection, and venous thrombosis.

Sponsors and collaborators

Lead sponsor

Cleveland Clinic Akron General

Other

Registry information

Official study title

Evaluation of the Efficacy of the Superficial Cervical Plexus Block in Reducing Pain Associated With Internal Jugular Central Lines

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Feb 23, 2022
Registry last updated
May 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.